Related Experiment Videos

[Congenital hypoprothrombinemia/dysprothrombinemia]

¹Department of Transfusion Medicine, Nagoya University Hospital.

Ryoikibetsu Shokogun Shirizu

|December 2, 1998

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.

Haemophilia : the official journal of the World Federation of Hemophilia·2013

Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.

Haemophilia : the official journal of the World Federation of Hemophilia·2012

An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.

Haemophilia : the official journal of the World Federation of Hemophilia·2011

Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.

Haemophilia : the official journal of the World Federation of Hemophilia·2011

See all related articles